Moreover, the calibration curves along with the goodness-of-fit assessments for the predicted outcomes in both tumor and normal cohorts indicated that PAK2 serves as a reliable biomarker for the diagnosis of HNSC. This evidence concerns the gene PAK2 and neoplasm.